NCT04166721View on ClinicalTrials.gov

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

March 30, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Esophageal CancerMetastatic Gastric Cancer
Interventions
DRUG

Atezolizumab

Immunotherapy

Trial Locations (1)

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

All Listed Sponsors
lead

Royal Marsden NHS Foundation Trust

OTHER

NCT04166721 - WaKING: Wnt and checKpoint INhibition in Gastric Cancer | Biotech Hunter | Biotech Hunter